Isabell Remus currently serves as Head, Biopharmaceuticals Europe for Sandoz, overseeing launch readiness and commercialization for the second largest, and rapidly growing, biosimilars market.
Under her leadership and in 2018 alone, Sandoz region Europe launched three new medicines including biosimilars adalimumab, infliximab and pegfilgrastim; increasing the total number of Sandoz biosimilars on market to eight. She is a member of the Biopharma Executive Committee as well as the Region Europe Leadership Team. Isabell is also the Chair of the Biosimilar Medicines sector group at Medicines for Europe.
Since joining Novartis in 2005, Isabell has taken on roles of increasing responsibility across both Novartis and Sandoz, most recently serving as Head, Biopharmaceuticals Western Europe; Head, Global Product Strategy and Commercialization Biosimilars and Oncology Injectables and Chief Executive Officer Specialty of Hexal AG and Managing Director of Sandoz Pharmaceuticals GmbH.
She has a breadth of proven leadership experience across global brand management, market access, commercial excellence, new products and portfolio over a variety of therapeutic areas including immunology, oncology, nephrology, gastroenterology and more.
Prior to joining Novartis / Sandoz, Isabell Remus worked for Procter & Gamble in Athens, Geneva and Frankfurt. She studied European Business Administration in London and Reutlingen.